Inke participates in RDD Europe 2025

Inke recently took part in RDD Europe 2025, held in Estoril, Portugal — a special edition that marked two decades of progress in the field of respiratory drug delivery. The event brought together leading experts from across the pharmaceutical industry to exchange insights and explore the latest innovations in inhalation therapies.

As a long-standing partner in the respiratory space, Inke contributed to discussions focused on key topics shaping the future of the sector. Among the highlights were:

• Dry Powder Inhalation (DPI): Presentations emphasized the importance of optimising formulations to achieve consistent aerodynamic performance and therapeutic efficacy.

• Pressurised Metered Dose Inhalers (pMDIs): Sessions addressed the industry’s transition toward sustainable propellants and the implications of new regulatory requirements.

• Nasal Drug Delivery: A growing area of interest, nasal delivery was explored as a versatile route for both systemic and targeted treatments.

Inke’s continued presence at events like RDD Europe reflects its commitment to delivering high-quality inhalation APIs and supporting the pharmaceutical community with deep technical expertise and regulatory knowledge.

Participation in the conference also provided valuable opportunities to connect with partners, share perspectives on current challenges, and stay aligned with the scientific and regulatory advancements shaping the global respiratory market.